Literature DB >> 8557917

Classification of death in antiarrhythmia trials.

A E Epstein1, M D Carlson, R N Fogoros, S L Higgins, F J Venditti.   

Abstract

OBJECTIVES: We sought to develop and apply a new scheme for the classification of death to be used in trials of antiarrhythmia treatments.
BACKGROUND: Because presently accepted classifications of death do not fully describe or tabulate all significant aspects of terminal events, nor do they consider unique aspects of arrhythmia investigations, a new classification scheme that addresses these issues is desirable.
METHODS: A classification scheme of deaths that occur in antiarrhythmia trials was developed using the following categories: 1) primary organ cause (cardiac [arrhythmic, nonarrhythmic or unknown], noncardiac or unknown); 2) temporal course (sudden, nonsudden or unknown); 3) documentation (witnessed, monitored [yes, no or unknown]); 4) operative relation (preoperative, perioperative or postoperative); and 5) system relation (procedure related, pulse generator related and lead related [yes, no or unknown]).
RESULTS: The classification scheme was used in a clinical trial of a new implantable cardioverter-defibrillator (1,250 patients, of whom 79 died) and used in an application for device market approval. Application of the classification to data reported using an older classification scheme is demonstrated.
CONCLUSIONS: We propose a descriptive classification scheme that 1) fully describes and tabulates all significant aspects of terminal events; 2) incorporates previously used categorizations of death and new categorizations that address unique aspects of arrhythmia investigations; and 3) tabulates sufficient data to allow comparison with other studies. Events in a clinical trial of implantable defibrillator therapy were classified using the new classification scheme.

Entities:  

Mesh:

Year:  1996        PMID: 8557917     DOI: 10.1016/0735-1097(95)00482-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee.

Authors:  Lorcan P McGarvey; Matthias John; Julie A Anderson; Michael Zvarich; Robert A Wise
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

2.  Sudden cardiac death: time to make a difference: Pro ICD.

Authors:  M J Schalij; L van Erven
Journal:  Neth Heart J       Date:  2006-12       Impact factor: 2.380

3.  Multicenter automatic defibrillator implantation trial: reduce inappropriate therapy (MADIT-RIT): background, rationale, and clinical protocol.

Authors:  Claudio Schuger; James P Daubert; Mary W Brown; David Cannom; N A Mark Estes; W Jackson Hall; Torsten Kayser; Helmut Klein; Brian Olshansky; Keith A Power; David Wilber; Wojciech Zareba; Arthur J Moss
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-07       Impact factor: 1.468

4.  QRS width and its impact on inducibility of ventricular arrhythmia at the time of electrophysiology study.

Authors:  Mahi Lakshmi Ashwath; Ike Okosun; Felix O Sogade
Journal:  J Natl Med Assoc       Date:  2005-05       Impact factor: 1.798

5.  The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy.

Authors:  David D Daly; Anbukarasi Maran; J Madison Hyer; Frederick Funke; Ashley Waring; Frank A Cuoco; J Lacy Sturdivant; Robert B Leman; Michael R Gold
Journal:  Pacing Clin Electrophysiol       Date:  2016-06-07       Impact factor: 1.976

6.  A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study.

Authors:  Maurizio Gasparini; Carlo Menozzi; Alessandro Proclemer; Maurizio Landolina; Severio Iacopino; Angelo Carboni; Ernesto Lombardo; François Regoli; Mauro Biffi; Valeria Burrone; Alessandra Denaro; Giuseppe Boriani
Journal:  Eur Heart J       Date:  2009-06-29       Impact factor: 29.983

7.  Detection of myocardial damage in patients with sarcoidosis.

Authors:  Manesh R Patel; Peter J Cawley; John F Heitner; Igor Klem; Michele A Parker; Wael A Jaroudi; Trip J Meine; James B White; Michael D Elliott; Han W Kim; Robert M Judd; Raymond J Kim
Journal:  Circulation       Date:  2009-11-02       Impact factor: 29.690

8.  Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial.

Authors:  Alan H Kadish; David Bello; J Paul Finn; Robert O Bonow; Andi Schaechter; Haris Subacius; Christine Albert; James P Daubert; Carissa G Fonseca; Jeffrey J Goldberger
Journal:  J Cardiovasc Electrophysiol       Date:  2009-07-01

9.  The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators.

Authors:  G N Kay; K A Ellenbogen; M Giudici; M M Redfield; L S Jenkins; M Mianulli; B Wilkoff
Journal:  J Interv Card Electrophysiol       Date:  1998-06       Impact factor: 1.900

10.  Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT).

Authors:  John D Fisher; Alfred E Buxton; Kerry L Lee; Douglas L Packer; Debra S Echt; Pablo Denes; Michael H Lehmann; John P DiMarco; Denis Roy; Gail E Hafley
Journal:  Am J Cardiol       Date:  2007-05-11       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.